Sökning: WFRF:(Krämer G)
> (2005-2009) >
Levetiracetam: a lo...
Levetiracetam: a long-term follow-up study of efficacy and safety.
-
Bauer, J (författare)
-
- Ben-Menachem, Elinor, 1945 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
Krämer, G (författare)
-
visa fler...
-
Fryze, W (författare)
-
Da Silva, S (författare)
-
Kasteleijn-Nolst Trenité, D G A (författare)
-
visa färre...
-
(creator_code:org_t)
- Hindawi Limited, 2006
- 2006
- Engelska.
-
Ingår i: Acta neurologica Scandinavica. - : Hindawi Limited. - 0001-6314 .- 1600-0404. ; 114:3, s. 169-76
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVES: To evaluate the efficacy and safety of long-term add-on treatment with levetiracetam 1,000-4,000 mg/day. PATIENTS AND METHODS: In this multicenter, open-label follow-up study, 505 patients, from 10 European countries, who had benefited from previous add-on treatment with levetiracetam in a clinical trial or compassionate-use program were enrolled; 274 (54.3%) stayed to the end. Most then continued levetiracetam by prescription or in a named patient program, where it was not yet commercially available. Mean treatment duration was 1,045 days (range: 24 days to >7 years). Median daily dosage was 3,000 mg/day (range: 250-6,000 mg/day), with 250 (49.5%) patients receiving levetiracetam for >3 years. RESULTS: Median total and partial seizure frequency per week over the evaluation period were 0.8 and 0.7; seizure frequency per week was generally stable over time and remained low. There was a probability of 6.6% of remaining seizure-free for the first 3 years, and of 18.9% of having a seizure-free period of at least 3 years at any time. Most adverse events were mild or moderate and unrelated to study drug. Levetiracetam was well tolerated, and provided stable seizure control during long-term treatment.
Nyckelord
- Adolescent
- Adult
- Aged
- Aged
- 80 and over
- Anticonvulsants
- administration & dosage
- adverse effects
- Child
- Dose-Response Relationship
- Drug
- Drug Administration Schedule
- Drug Therapy
- Combination
- Epilepsy
- drug therapy
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Piracetam
- administration & dosage
- adverse effects
- analogs & derivatives
- Treatment Outcome
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas